- About us
- Join Putnam
Our cell and gene therapy experts offer a deep analysis on the current opportunities and challenges of cell therapies for solid tumors.
The landscape of cell therapies for solid tumors has grown exponentially in recent years with several hundred in development worldwide. However, unlike hematologic malignancies, where several cell therapies have gained FDA approval, very few of the pipeline assets for solid tumors have reached pivotal trials, and those that have are for rare cancers. Proof-of-principle has yet to be established for cell therapies for more common epithelial cancers. Iterative studies are needed to continue to improve the potency and efficacy of cell therapies for such cancers, with the goal of demonstrating durable remissions in larger proportions of patients. This is easier said than done, as solid tumors present unique challenges to cell therapy, ranging from poor trafficking and infiltration and inadequate antigen recognition to lack of functional persistence. In this whitepaper we review the current state of solid tumor cell therapies and assess emerging approaches for expanding the target space with optimal antigens, combating resistance through multi-antigen targeting, and improving antigen recognition and signaling.
Putnam aimed to conduct an aggregate DCEA of two NSCLC treatments recommended by NICE, and identify key drivers of the analysis.
Our Putnam PHMR colleagues delivered an in-depth analysis on the burden of patient hospitalizations in France as a result of COVID-19. The study...